Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma plc (RPRX), sold 100,000 shares at $58.51 ($5.9M) on 2026-09-22, disclosed to the SEC on 2026-09-24.
Scheduled sale ($5.9M) by EVP & Chairman, Partnering under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.51 | 96,073 | $5.6M | 96.0% |
| 2 | $58.93 | 3,927 | $231K | 4.0% |
| Total | $58.53 avg | 100,000 | $5.9M | 100% |
| Filing → |
| RPRX | SELL | 2026-06-25 | $8.2M | — | Filing → |
| RPRX | BUY | 2020-06-23 | $2.0M | — | Filing → |